MAI Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,189
| Closed | -$218K | – | 865 |
|
|
2021
Q2 | $218K | Buy |
+1,189
| New | +$204K | ﹤0.01% | 682 |
|
|
2021
Q1 | – | Sell |
-1,754
| Closed | -$274K | – | 790 |
|
|
2020
Q4 | $274K | Sell |
1,754
-354
| -17% | -$45.5K | 0.01% | 556 |
|
|
2020
Q3 | $241K | Sell |
2,108
-612
| -23% | -$66K | 0.01% | 510 |
|
|
2020
Q2 | $305K | Sell |
2,720
-225
| -8% | -$23.9K | 0.01% | 455 |
|
|
2020
Q1 | $264K | Sell |
2,945
-1,317
| -31% | -$129K | 0.01% | 455 |
|
|
2019
Q4 | $461K | Sell |
4,262
-2,507
| -37% | -$268K | 0.02% | 402 |
|
|
2019
Q3 | $663K | Sell |
6,769
-292
| -4% | -$32.9K | 0.03% | 310 |
|
|
2019
Q2 | $925K | Buy |
+7,061
| New | +$910K | 0.04% | 255 |
|
|
2017
Q2 | – | Sell |
-1,682
| Closed | -$204K | – | 477 |
|
|
2017
Q1 | $204K | Sell |
1,682
-3,028
| -64% | -$390K | 0.01% | 414 |
|
|
2016
Q4 | $576K | Sell |
4,710
-491
| -9% | -$60.1K | 0.04% | 247 |
|
|
2016
Q3 | $637K | Buy |
5,201
+920
| +21% | +$118K | 0.05% | 240 |
|
|
2016
Q2 | $500K | Buy |
4,281
+1,358
| +46% | +$193K | 0.04% | 271 |
|
|
2016
Q1 | $407K | Buy |
2,923
+273
| +10% | +$40.1K | 0.03% | 295 |
|
|
2015
Q4 | $505K | Buy |
2,650
+596
| +29% | +$104K | 0.04% | 270 |
|
|
2015
Q3 | $321K | Buy |
2,054
+549
| +36% | +$100K | 0.02% | 334 |
|
|
2015
Q2 | $272K | Buy |
+1,505
| New | +$260K | 0.02% | 386 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM